[Construction and immunogenicity of recombinant Canine adenovirus type 2 with the external part of glycoprotein of rabies virus].
The cases of rabies increase greatly in recent years in China and rabies continues to be a serious problem in developing countries due to the reservoirs of Rabies virus in dogs and wildlife vectors. The control of rabies depends on the development of safe, effective, economical vaccines that may be used for preexposure vaccination in animals. For this purpose, the external part of glycoprotein gene of Rabies virus strain SRV9 (RVG) was amplified by the RT-PCR and cloned into pEGFP-C1 with replacement of the GFP gene. The expression cassette pERVG2 is composed of CMV promoter, external glycoprotein gene and SV40 early mRNA polyadenylation signal. The expression cassette was released by Ase I /Mlu I double digestion and it was cloned rightwards and leftwards into Canine adenovirus type 2(CAV-2) E3 region plasmid pVAXE3 in which E3 region was deleted partly by Ssp I /Dra III digestion. After the replacement of CAV-2 E3 region in plasmid pCAV-2 which contains CAV-2 genome with the recombinant E3 region, recombinant CAV-2 genome plasmid was obtained. Recombinant CAV-2 genome was released from plasmid by Asc I /Cla I digestion, and then transfected into MDCK cells. Two replication-competent recombinant CAV2 expressing Rabies Virus external part of glycoprotein were produced. Vaccination experiment showed that the recombinant viruses can elicit an efficient antibody response in dogs.